What Would You Pay to Stay Alive?
What Next | Daily News and Analysis
00:00
Celgene's Market Monopoly and Drug Pricing Dilemmas
This chapter explores the monopoly held by Celgene over the cancer drug Revlimid and the regulatory hurdles that prevented generic competition. It addresses the financial implications of exorbitant drug costs on patients and criticizes the ongoing inefficiencies in the healthcare system. The discussion also highlights the efforts needed for reform in U.S. drug pricing, contrasting it with more successful models in other countries.
Transcript
Play full episode
